We were delighted to talk to Diego Maselli (University of Texas Health Science Center at San Antonio, TX, US) around the effects of Body Mass Index (BMI) on response to the triple therapy of fluticasone furoate, umeclidinium, and vilanterol in patients with inadequately controlled asthma (Clinical Trial Identifier: NCT02924688).
The abstract ‘CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting b2-agonists (ICS/ LABA).’ (ABSTRACT NUMBER: 176) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What has the CAPTAIN trial taught us about the clinical utility of the single inhaler triple therapy of fluticasone furoate, umeclidinium, and vilanterol in the treatment of patients with uncontrolled asthma? (0:23)
- What were the results of your analysis of the CAPTAIN study data in subgroups defined by BMI? (1:18)
- What are the implications of these findings for asthma therapy? (3:06)
- What are the remaining unanswered questions regarding the use of this triple therapy? (3:50)
Disclosures: Diego Maselli discloses consulting fees from GSK, AstraZeneca, Sanofi/Regeneron and Amgen.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!